Home » Pfizer, Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders
Pfizer, Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders
Pfizer Inc. and Bristol-Myers Squibb Company announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007. Pfizer’s DGAT- 1 discovery program includes advanced pre-clinical compounds with potential applications for the treatment of metabolic disorders, including obesity and diabetes. The program also includes DGAT-1 inhibitors in-licensed by Pfizer from Bayer Pharmaceuticals Corporation in June 2006, including a pre-clinical compound (known as PF-04415060 or BAY 74-4113) originally discovered by Bayer.
BioSpace
Upcoming Events
-
07May
-
14May
-
30May